HCV is a major cause of liver cirrhosis and hepatocellular carcinoma. Current antiviral treatment is limited by drug resistance, toxicity and high costs 1 . Although newly developed antiviral substances target ing HCV protein processing have been shown to improve virological response, toxicity and resistance remain major challenges 2 . Thus, new antiviral preventive and therapeutic strategies are urgently needed. Because HCV entry is required for initiation, dissemina tion and maintenance of viral infection, it is a promising target for antiviral therapy 3, 4 .
HCV entry is a multistep process involving viral envelope glyco proteins as well as several cellular attachment and entry factors 5 . Attachment of the virus to the target cell is mediated through bind ing of HCV envelope glycoproteins to glycosaminoglycans 6 . HCV is internalized in a clathrindependent endocytic process requiring CD81 (ref. 7) , scavenger receptor type B class I (SRBI) 8 , claudin1 (CLDN1) 9 and occludin (OCLN) 10 . To elucidate the functional role of host cell kinases within the HCV entry process, we performed a functional RNAi screen.
RESULTS

Host cell kinases are host cofactors for HCV entry
Using a siRNA screen, we identified a network of kinases with functional impact on HCV entry (Supplementary Results, Supplementary Tables 1 and 2 and Supplementary Figs. 1 and 2) . To study the relevance of the identified kinases on the HCV life cycle, we further validated and characterized the functional impact of epi dermal growth factor receptor (EGFR), ephrin receptor A2 (EphA2) and cell division cycle 2 kinase (CDC2) (Supplementary Results and Supplementary Fig. 3 ) on HCV entry. We focused on EGFR and EphA2 because they are key components in the identified networks ( Supplementary Fig. 2c ), they are highly expressed in human liver (Supplementary Table 2 ) and their kinase function is inhibited by clinically approved protein kinase inhibitors (PKIs) [11] [12] [13] , allowing us to explore the potential of these molecules as therapeutic targets.
Using individual siRNAs, we first confirmed that silencing of mRNAs reduced EGFR and EphA2 mRNA and protein expression (Fig. 1a,b and Supplementary Fig. 4a,b) . Infection of siEGFR or Hepatitis C virus (HCV) is a major cause of liver disease, but therapeutic options are limited and there are no prevention strategies. Viral entry is the first step of infection and requires the cooperative interaction of several host cell factors. Using a functional RNAi kinase screen, we identified epidermal growth factor receptor and ephrin receptor A2 as host cofactors for HCV entry. Blocking receptor kinase activity by approved inhibitors broadly impaired infection by all major HCV genotypes and viral escape variants in cell culture and in a human liver chimeric mouse model in vivo. The identified receptor tyrosine kinases (RTKs) mediate HCV entry by regulating CD81-claudin-1 co-receptor associations and viral glycoprotein-dependent membrane fusion. These results identify RTKs as previously unknown HCV entry cofactors and show that tyrosine kinase inhibitors have substantial antiviral activity. Inhibition of RTK function may constitute a new approach for prevention and treatment of HCV infection. a r t i c l e s 5 9 0 VOLUME 17 | NUMBER 5 | MAY 2011 nature medicine siEphA2treated cells by cell culture-derived HCV (HCVcc) was markedly reduced, as compared to control siRNAtreated cells indi cating that both EGFR and EphA2 are involved in the initiation of a productive infection ( Fig. 1c and Supplementary Fig. 4c ). Silencing of kinase expression inhibited the entry of HCV pseudoparticles (HCVpp) derived from major genotypes, including highly diverse HCV strains 14 ( Fig. 1d and Supplementary Fig. 4d ).The effects of silencing of endogenous EGFR or EphA2 on HCV infection were rescued by RNAiresistant ectopic expression of wildtype EGFR or EphA2 (Fig. 1e,f and Supplementary Fig. 4e,f) , largely excluding the possibility of offtarget effects causing the observed phenotype. Furthermore, silencing and rescue experiments using wellcharacterized lentiviral vectors expressing EGFRspecific shRNA showed a key role for EGFR in HCV entry into primary human hepatocytes (PHHs) (Fig. 1f) . We then assessed the functional impact of EGFR as a cofactor for HCV entry by expressing human EGFR in mouse hepatoma cell lines engineered to express the four human entry factors CD81, SRBI, CLDN1 and OCLN (AML12 4R; Supplementary Fig. 5 ). Cell surface expression of human EGFR in AML12 4R cells markedly enhanced the susceptibility of mouse cells to HCVpp entry (Supplementary Fig. 5 ).
RTK kinase function is relevant for HCV entry
We used PKIs to further study the functional relevance of the identified kinases for HCV entry and infection. Erlotinib (an EGFR inhibitor) and dasatinib (an EphA2 inhibitor) impaired HCV entry and infection in a dosedependent manner without a detectable effect on replication of the corresponding subgenomic replicon (Fig. 2, Supplementary  Fig. 6 and Supplementary Fig. 7 ). The halfmaximal inhibitory con centration (IC 50 ) values for erlotinib and dasatinib to block HCVpp entry (erlotinib, 0.45 ± 0.09 µM; dasatinib, 0.53 ± 0.02 µM) and HCVcc infection (erlotinib, 0.53 ± 0.08 µM; dasatinib, 0.50 ± 0.30 µM) of human hepatoma Huh7.5.1 cells were comparable ( Fig. 2a and Supplementary Fig. 7a,b) . These data indicate that inhibiting RTKs by erlotinib and dasatinib has a marked effect on HCV entry.
To evaluate the effects of the inhibitors on HCV entry into cells more closely resembling the HCV target cells in vivo, we investigated HCVpp entry into polarized HepG2CD81 hepatoma cells 15 and PHHs. PKIs markedly and significantly (P < 0.005) inhibited HCVpp entry into polarized HepG2CD81 cells ( Fig. 2c and Supplementary Fig. 7d ) and PHHs ( Fig. 2d and Supplementary Fig. 7e ). We obtained similar results for infection of PHHs with HCVcc and serumderived HCV ( Fig. 3 and Supplementary Fig. 7 ), confirming the role of the kinases as auxiliary host cell cofactors in models that more closely mimic in vivo infection.
A specific effect of erlotinib on EGFRmediated HCV entry was further confirmed by the inhibition of HCV entry and infection by other EGFR inhibitors. The EGFR inhibitors gefitinib and lapatinib markedly inhibited HCVpp entry and HCVcc infection in PHHs and Huh7.5.1 cells similarly to erlotinib (Fig. 2e,f) . The specificity of the PKIs in preventing HCV entry was further corroborated by their lack of an effect on murine leukemia virus and measles virus entry ( Fig. 2c and Supplementary Fig. 8 ). Moreover, PKI treatment of RTKsilenced Huh7.5.1 cells reversed the rescue of HCV entry conferred by expressing EGFR and EphA2 in trans (data not shown). Taken together, these results suggest that the RTK kinase function is necessary for efficient HCV entry.
RTK-specific ligands and antibodies modulate HCV entry
We assessed virus entry in the presence of RTKspecific ligands and antibodies. Epidermal growth factor (EGF) and transforming growth factorα (TGFα) are wellcharacterized EGFR ligands whose bind ing promotes receptor dimerization and subsequent phosphorylation of the intracytoplasmic kinase domain 16 . To confirm the biological activity of EGFRspecific reagents in the target cells of our HCV model systems, we first studied their effect on EGFR phosphoryla tion. Preincubation of PHHs with EGF markedly increased basal 40 . Data are expressed as percentage HCVpp entry relative to Ctrl cells or as percentage EGFR expression normalized for β-actin expression (means ± s.d. from four independent experiments in triplicate). ***P < 0.0005. levels of EGFR phosphorylation (Fig. 3a) . In contrast, EGF had no effect on the phosphorylation of cmer protooncogene tyrosine kinase (MERTK), an unrelated kinase (Fig. 3a) . EGFinduced enhancement of basal EGFR phosphorylation was markedly inhibited by erlotinib and an EGFRspecific antibody ( Fig. 3a) , indicating their specific effect on EGFR phosphorylation and activation. We next examined the role of EGFR ligands on HCV entry. serumstarved Huh7.5.1 cells, polarized HepG2CD81 cells and PHHs (Fig. 3b,c) , whereas TGFβ had no effect (data not shown). These data suggest that direct interaction of EGF or TGFα with the EGFR ligand binding domain modulates HCV entry. The higher affinity of EGF for EGFR on hepatocytes 17 may explain the differences between EGF and TGFα in enhancing HCVpp entry. Erlotinib, at doses used in HCV entry inhibition experiments, reversed the enhancing effects of EGF (Fig. 3d) and TGFα (data not shown) on HCV entry. These data con firm that erlotinib inhibits HCV entry by modulating EGFR activity. We screened a large panel of EGFRspecific antibodies and identified a monoclonal human EGFRspecific antibody that bound PHHs (Fig. 3e) and inhibited HCV entry into PHH in a dosedependent manner (Fig. 3f) , with an IC 50 value of 1.82 ± 0.3 µg ml −1 . The antibody inhibi ted EGFR phosphorylation (Fig. 3a) and reversed the EGFinduced enhancement of HCV entry (Fig. 3g) . Ligandinduced enhancement and EGFRspecific antibody-mediated inhibition of HCV entry were also observed for infection of PHHs with HCVcc (Fig. 3h) and with serumderived HCV (Fig. 3i) . Taken together, these results suggest that the EGFR ligandbinding domain is relevant for HCV entry. Similarly, EphA2 ligands and EphA2specific antibodies modulated HCV entry, suggesting a functional relevance of the EphA2 ligandbinding domain for HCV entry (Supplementary Results and Supplementary Fig. 9 ).
Binding of EGF and TGFα markedly enhanced entry of HCVpp into
RTKs promote CD81-CLDN1 associations and membrane fusion To understand the mechanistic role of EGFR and EphA2 in HCV entry, we first investigated whether the RTKs regulate SRBI, CD81, CLDN1 and OCLN expression. However, silencing RTK expression with specific siRNAs or inhibiting RTK function with PKIs had no significant effect on HCV entry factor expression (Fig. 4a,b) .
Next, we aimed to finemap the entry steps affected by the RTKs. Viral attachment is the first step of viral entry. To ascertain whether PKImediated inhibition of RTK function modulates HCV binding, we used a surrogate model that measures binding of the recombinant soluble form of HCV envelope glycoprotein E2 to Huh7.5.1 cells 18 . RTKspecific antibodies or silencing RTK expression by siRNAs had no significant effect on E2 binding of target cells, whereas preincu bation with SRBI-specific antibodies or silencing SRBI expression markedly reduced E2 binding ( Fig. 4c and Supplementary Fig. 10a) . Furthermore, in contrast to the case with CD81 and SRBI 19 , RTKs did not increase cellular E2 binding when expressed on the cell surface of Chinese hamster ovary cells (data not shown). These data suggest that RTKs do not modulate HCV binding to target cells.
After viral envelope binding, HCV enters its target cell in a multistep temporal process. To identify the time at which the PKIs exert their effects, we used a wellcharacterized assay allowing us to investigate 25 . Means ± s.d. from three independent experiments in triplicate are shown. *P < 0.05; ***P < 0.0005. Unless otherwise indicated, EGFR-specific and control mAbs: 10 µg ml −1 ; EGF: 1 µg ml −1 ; erlotinib: 10 µM.
whether an inhibitory molecule interferes with viral envelope binding or affects entry steps after binding of the virus to the target cell [19] [20] [21] . In contrast to heparin (an inhibitor of HCV binding) but similarly to CD81 and SRBI-specific antibodies and concanamycin A (an inhibitor of endosomal acidification), PKIs inhibited HCVcc infection when added after virus binding to target cells (Fig. 4d) . We obtained similar results for HCVpp entry into PHHs after treatment with an EGFRspecific antibody (Fig. 4e) . These data suggest that the RTKs act at postbinding steps of viral entry.
To further elucidate the entry steps targeted by the RTKs, we performed a kinetic entry assay 19, 21 (Supplementary Fig. 10b) . Notably, the halfmaximal times (t 1/2 ) for erlotinib (t 1/2 = 20 min) and dasatinib (t 1/2 = 26 min) to inhibit HCV entry were similar to the halfmaximal time of a CD81specific antibody (t 1/2 = 26 min) ( Fig. 4f and Supplementary Fig. 10d) . Moreover, similar to conca namycin A, PKIs also had an inhibitory effect when added at late times (60-80 min) after infection (Fig. 4 and Supplementary Fig. 10 ). We further confirmed the role of EGFR as a postbinding factor by kinetic assays under serumfree conditions. In line with previous reports 22 , HCV entry kinetics were delayed under serumfree condi tions (Fig. 4g) . EGF significantly (P < 0.05) reduced the time needed for HCVcc to escape the inhibiting effects of a CD81specific antibody in serumstarved cells from 44 ± 8 min to 27 ± 6 min (mean ± s.d. of three independent experiments), suggesting that EGF markedly and significantly (P < 0.05) accelerates the rate of HCV entry (Fig. 4g) . In summary, these data suggest that EGFR is required for efficient viral entry by modulating early and late steps of postbinding events.
Postbinding steps of HCV entry are mediated by the HCV entry factors SRBI, CD81, CLDN1 and OCLN. As PKIs inhibited HCV entry at similar timepoints as a CD81specific antibody, we investi gated whether PKIs interfere with CD81CLDN1 coreceptor interac tions using a fluorescence resonance energy transfer (FRET)based assay 15, 23, 24 . PKIs significantly (P < 0.0005) reduced CD81CLDN1 FRET in polarized HepG2 cells (Fig. 4h and Supplementary Fig. 10e) . We obtained similar results with RTKspecific siRNAs (Fig. 4h and  Supplementary Fig. 10e) , confirming that the observed inhibition is RTK specific and not mediated by offtarget effects of the PKIs. These results suggest that EGFR and EphA2 regulate the formation of the CD81CLDN1 coreceptor complexes that are essential for HCV entry 23 and that erlotinib and dasatinib inhibit HCV entry by interfer ing with the CD81CLDN1 coreceptor association.
As kinetic assays showed that PKIs inhibited late steps of viral entry ( Fig. 4f and Supplementary Fig. 10d) , we investigated the impact of these kinases in a viral glycoprotein-dependent cellcell fusion assay 25 . Both PKIs significantly (P < 0.05) inhibited membrane fusion of cells expressing glycoproteins derived from genotypes 1a (H77), 1b (Con1) and 2a (J6) (Fig. 4i and Supplementary Fig. 10f) , whereas the EGFR ligand EGF enhanced membrane fusion of cells expressing these HCV envelope glycoproteins (Fig. 4i) . In contrast, neither erlotinib nor EGF had a marked effect on the membrane fusion of cells expressing measles virus envelope glycoproteins (Fig. 4i) . We obtained comparable results in EGFR and EphA2silenced cells (Fig. 4i , data not shown) confirming that the RTKs are involved in viral glycoprotein-dependent membrane fusion.
Impact of RTKs in cell-to-cell transmission and viral spread
To investigate the relevance of RTKmediated virushost interactions for celltocell transmission and viral spread, we used a celltocell transmission assay 26 ( Fig. 5a-c) . Erlotinib and dasatinib significantly (P < 0.0005) blocked HCV celltocell transmission during short term coculture experiments (24 h) ( Fig. 5d-f and Supplementary  Fig. 11a-c) . We also observed a marked inhibition of celltocell trans mission when we silenced EGFR and EphA2 with specific siRNAs: infec tion of GFPpositive target cells directly correlated with RTK cell surface expression (Fig. 5g,h and Supplementary Fig. 11d,e) . Because PKIs inhibited celltocell transmission, we investigated whether erlotinib and dasatinib also impede viral spread in the HCVcc system when added after infection during longterm experiments. Both PKIs inhibited viral spread in a dosedependent manner for up to 14 d when added 48 h after infection to HCVinfected cells ( Fig. 5f and Supplementary Fig. 11c ).
Cell viability was not affected by longterm PKI treatment. We also observed a specific decrease in viral spread in cells with silenced RTK expression ( Fig. 5i and Supplementary Fig. 11f ). Taken together, these data indicate that PKIs reduce viral spread and suggest a key function of these RTKs in celltocell transmission and dissemination.
Erlotinib inhibits HCV infection in vivo
To address the in vivo relevance of the identified virushost inter actions, we assessed the effect of erlotinib on HCV infection in the chimeric urokinase plasminogen activator-severe combined immunodeficiency (uPASCID) mouse model [27] [28] [29] . Erlotinib dos ing and administration was performed as described previously for cancer xenograft models 30 and is indicated in Figure 6 . Erlotinib treatment significantly (P < 0.05) delayed the kinetics of HCV infection (Fig. 6) . The median time to reach steadystate levels of infection increased from 15 d (placebo group) to 30 d (erlotinib group) (median of pooled data from six placebotreated and eight erlotinibtreated mice). Furthermore, erlotinib treatment decreased steadystate HCV RNA levels by more than 90% (mean of pooled data from six placebotreated and eight erlotinibtreated mice; P < 0.05). After discontinuation of treatment, viral load reached simi lar levels as in placebotreated mice (Fig. 6) . The treatment was well tolerated and did not induce any marked changes in safety parameters such as serum concentrations of alanine transaminase, albumin or body weight (data not shown). Erlotinib plasma concentrations were similar to those described previously in preclinical studies of cancer mouse models 30 (data not shown). Taken together, these data suggest that EGFR acts as a cofactor for HCV entry and dissemination in vivo and show that erlotinib has antiviral activity in vivo.
DISCUSSION
Using RNAi screening, we uncovered a network of kinases that have a functional impact on HCV entry and identified EGFR and EphA2 as previously unrecognized cofactors for HCV entry. This identifi cation of kinases as HCV entry factors advances knowledge on the molecular mechanisms and cellular requirements of HCV entry, and the discovery of PKIs as candidate antivirals defines a potential new strategy for preventing and treating HCV infection. EGFR is a RTK that regulates a number of key processes, including cell proliferation, survival, differentiation during development, tissue homeostasis and tumorigenesis 31 . EphA2 mediates cell positioning, cell morphology, polarity and motility 32 . As PKIs had no effect on HepG2 polarization (Supplementary Fig. 12) , it is unlikely that changes in polarity explain their mode of action. Our results rather highlight a role of these RTKs in the formation of HCV entry factor complexes and membrane fusion. EGF accelerated HCV entry, sug gesting that EGFR plays a key part in the HCV entry process, allow ing HCV to efficiently enter its target cell. Applying FRET proximity analysis, we found that inhibition of EGFR or EphA2 activity reduced CD81CLDN1 association. As EGFR activation has been reported to promote CLDN1 redistribution 33, 34 , and we found that the level of CD81 or CLDN1 cell surface expression was not altered by EGFR silencing (Fig. 4a) , we hypothesize that EGFR activation modulates intracellular or cell surface trafficking of CLDN1, CD81 or both, which is necessary to form viral envelopeCD81CLDN1 coreceptor complexes 19, 23, 24 . The observations that erlotinib inhibits late steps in the kinetic infection assay and in the HCV cell fusion assay suggest a functional role for EGFR in pHdependent fusion of viral and host cell membranes 25, 35 .
Our functional experiments with specific ligands, antibodies and kinase inhibitors implicated both ligandbinding and kinase domains of EGFR in promoting HCV entry. EGFR ligands enhanced HCV infection, and an EGFRspecific antibody inhibited HCV infec tion. This antibody binds between ligandbinding domain III and the autoinhibition (tether) domain IV of the extracellular part of EGFR 36 and prevents EGF and TGFα-induced receptor dimeriza tion 37 . Thus, it is likely that receptor dimerization and/or the domain targeted by the antibody are required for HCV entry. Taken together, these findings support a model in which EGFRligand binding acti vates the EGFR kinase function that is required for HCV entry.
We obtained similar results for EphA2, where antibodies specific for the extracellular domain of EphA2 inhibited HCV entry into PHHs and EphA2 surrogate ligands decreased viral entry. Because addition of surrogate ligands only reduced HCV entry to a small extent, it is a b c conceivable that the effect of EphA2 on HCV entry could be both ligand independent and ligand dependent. This is consistent with other well characterized EphA2 functions such as cell invasion and migration 38 . Given that our functional and mechanistic studies indicate that the expression and activity of EGFR and EphA2 seem to be involved in similar entry steps, it is likely that both RTKs are part of the same entry regulatory pathway. Because erlotinib and EGF modulated entry of HCVpp but showed minimal effects on the unrelated viruses stud ied (Supplementary Fig. 8) , it is likely that the molecular mechanisms that we uncovered are most relevant for HCV entry.
Finally, our results have clinical implications for the prevention and treatment of HCV infection, as they show that licensed PKIs have antiviral activity in vitro and in vivo and identified a monoclonal RTKspecific antibody that inhibits viral entry. Thus, targeting RTKs as HCV entry factors using small molecules or antibodies may consti tute a new approach to prevent and treat HCV infection and address antiviral resistance.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
